Genelux (GNLX) Capital Expenditures (2022 - 2026)

Genelux's (GNLX) quarterly Capital Expenditures came in at $921000.0 in Q1 2026, up 2970.0% year-on-year from $30000.0 in Q1 2025, and up 111.24% quarter-over-quarter from $436000.0 in Q4 2025.

Genelux (GNLX) Capital Expenditures (2022 - 2026) Analysis & Trends

Genelux's Capital Expenditures history runs 5 years deep, the most recent figure standing at $921000.0 for Q1 2026.

  • On a quarterly basis, Capital Expenditures rose 2970.0% year-over-year to $921000.0 in Q1 2026; TTM through Mar 2026 was $2.0 million, a 422.05% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, up 188.19% from the prior year.
  • Capital Expenditures improved to $921000.0 in Q1 2026 per GNLX's latest filing, from $436000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $921000.0 in Q1 2026 and bottomed at $15000.0 in Q1 2022.
  • The 5-year median for Capital Expenditures is $171500.0 (2024), against an average of $245714.3.
  • Across the five-year window, Capital Expenditures plunged 90.25% in 2024 and jumped 2970.0% in 2026, its largest moves.
  • Year by year, Capital Expenditures stood at $15000.0 in 2022, then soared by 1520.0% to $243000.0 in 2023, then tumbled by 60.49% to $96000.0 in 2024, then soared by 354.17% to $436000.0 in 2025, then soared by 111.24% to $921000.0 in 2026.
  • Per Business Quant, the three latest GNLX Capital Expenditures figures stand at $921000.0 (Q1 2026), $436000.0 (Q4 2025), and $517000.0 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Capital Expenditures (Qtr)
1 Oculis Holding AG 67,102.16 Bn 67,101.87 Bn - -8,939.03
2 Nanobiotix 1,909.44 Bn 1,909.38 Bn - -
3 Akari Therapeutics 989.71 Bn 989.71 Bn - -
4 BeOne Medicines 471.58 Bn 466.79 Bn 1.35 Bn 43.25 Mn
5 Vertex Pharmaceuticals 121.97 Bn 114.72 Bn 2.59 Bn 133.40 Mn
6 Regeneron Pharmaceuticals 69.93 Bn 61.18 Bn 3.31 Bn 230.60 Mn
7 Belite Bio 62.68 Bn 62.68 Bn - -
8 Argenx Se 55.80 Bn 50.61 Bn 1.41 Bn -
9 Alnylam Pharmaceuticals 37.37 Bn 34.36 Bn 959.66 Mn 21.83 Mn
10 Genelux 128.92 Mn 128.92 Mn - 921,000.00

Historic Data

Download Data
DateValue
Mar 31, 2026 921,000.00
Mar 31, 2026 921,000.00
Dec 31, 2025 436,000.00
Dec 31, 2025 436,000.00
Sep 30, 2025 517,000.00
Sep 30, 2025 517,000.00
Jun 30, 2025 115,000.00
Jun 30, 2025 115,000.00
Mar 31, 2025 30,000.00
Mar 31, 2025 30,000.00
Dec 31, 2024 96,000.00
Dec 31, 2024 96,000.00
Sep 30, 2024 27,000.00
Sep 30, 2024 27,000.00
Jun 30, 2024 228,000.00
Jun 30, 2024 228,000.00
Mar 31, 2024 30,000.00
Mar 31, 2024 30,000.00
Dec 31, 2023 243,000.00
Dec 31, 2023 243,000.00